|
More on Estybon
Hey Cheri!
Just ran across this article on Estybon in the MDS Beacon. This is an easier-to-read summary of the same study that Birgitta found for us.
Here are some highlights:
Quote:
|
Results of a recent analysis confirm that treatment with the investigational drug Estybon may prolong survival in myelodysplastic syndromes patients who can no longer be effectively treated with Vidaza or Dacogen. . . .The median overall survival time for all patients was 36 weeks. The group that received 1,800 mg Estybon every day for three consecutive days every other week had the longest median overall survival time of 49 weeks. The researchers found that 54 percent of patients achieved a complete bone marrow response or a greater than 50 percent reduction in the number of immature bone marrow cells. The median overall survival time for these patients was 44 weeks. Patients who achieved stable disease with Estybon (38 percent) had a median survival time of 40 weeks. Patients who experienced disease progression (8 percent) had a median survival time of 16 weeks. According to the study authors, Estybon was well tolerated. They did not observe any cases of blood-related side effects.
|
Good luck!
Greg
__________________
Greg, 59, dx MDS RCMD Int-1 03/10, 8+ & Dup1(q21q31). NIH Campath 11/2010. Non-responder. Tiny telomeres. TERT mutation. Danazol at NIH 12/11. TX independent 7/12. Pancreatitis 4/15. 15% blasts 4/16. DX RAEB-2. Beginning Vidaza to prep for MUD STC. Check out my blog at www.greghankins.com
Last edited by Greg H : Thu Jun 30, 2011 at 12:25 PM.
Reason: Added note referencing Birgitta's post.
|